CN108395461B - 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 - Google Patents
7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 Download PDFInfo
- Publication number
- CN108395461B CN108395461B CN201710066556.4A CN201710066556A CN108395461B CN 108395461 B CN108395461 B CN 108395461B CN 201710066556 A CN201710066556 A CN 201710066556A CN 108395461 B CN108395461 B CN 108395461B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- compound
- solution
- beta
- glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229930182470 glycoside Natural products 0.000 title claims description 16
- 229940124599 anti-inflammatory drug Drugs 0.000 title abstract description 10
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 title description 17
- 235000007708 morin Nutrition 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- -1 flavonoid glycoside compound Chemical class 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- 238000010828 elution Methods 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000007791 liquid phase Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 229930182486 flavonoid glycoside Natural products 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 28
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- 206010014025 Ear swelling Diseases 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 240000001307 Myosotis scorpioides Species 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- OHVGNSMTLSKTGN-BTVCFUMJSA-N [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical group [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OHVGNSMTLSKTGN-BTVCFUMJSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于天然药物化学领域,提供了一个黄酮苷类化合物及其制备方法和其在制备抗炎药物中的应用,本药物是从桑枝药材中提取分离纯化得到,实验显示其具有显著的抗炎效果,该化合物结构式如下:
Description
技术领域
本发明涉及一种黄酮苷化合物及其制备方法和用途;具体涉及7,4′-O-β-D-葡萄糖桑色素苷及其制备方法和其在制备抗炎药物中的应用。
背景技术
炎症是十分常见而又重要的基本病理过程,体表的外伤感染和各器官的大部分常见病和多发病都属于炎症性疾病。抗炎药有两大类:一类是甾体抗炎药,即肾上腺皮质所分泌的糖皮质激素氢化可的松及其人工合成的衍生物。另一类是非甾体抗炎药(NSAIDs),即医疗实践中所指的解热镇痛抗炎药如阿司匹林、保泰松、塞来昔布等。
NSAID大多为有机酸,与血浆蛋白有高度结合力,从而增加药物在炎症部位的浓度而发挥作用。NSAID在抗炎作用的同时,由于抑制了前列腺素的合成,从而造成了对胃肠道的副作用。其主要表现为胃、十二指肠溃疡引起的上消化道出血。据美国FDA统计,服用NSAID3个月的患者,胃肠道溃疡、出血和穿孔的发生率为1%~2%,服用1年的患者则发生率在2%~5%。少数病人发生过敏反应,如风疹、过敏性鼻炎、哮喘。这是由于前列腺素合成的减少,造成小血管和支气管痉挛所致。NSAID主要毒性反应除胃肠道和肾脏方面外,尚有中枢神经系统、血液系统、皮肤和肝脏等副作用,这些副作用的发生常与剂量有关。
桑色素具有抗癌、抗炎、抗氧化等广泛的药理作用,临床用于抗病毒感染、治疗头痛、冠心病及慢性炎症的治疗,但其水溶性、脂溶性均较差,限制了它在临床中的应用。另有研究表明桑色素的口服生物利用度极低,不仅脂溶性和水溶性较差,更为重要的原因是:(1)桑色素极易被P糖蛋白外排(李燕等《黄酮衍生物作为P糖蛋白抑制剂的构效关系研究》,大连理工大学学报,2007,47(1):15-20);(2)黄酮类化合物体内清除速率与其结构有关,如5、7、4′位没有羟基时,会保护药物不被清除,而桑色素在这三个位点均有羟基,清除很快。因此,开发安全有效的天然抗炎药是现代医学关注的焦点。
发明内容
本发明的目的是提供了一个7,4′-O-β-D-葡萄糖桑色素苷类化合物及其制备方法和其在制备抗炎药物中的应用。
本发明提供了一种7,4′-O-β-D-葡萄糖桑色素苷类化合物,其结构式如下:
该化合物为从桑枝中提取所得,为黄棕色不定形粉末,其纯度达到90%-98%。
其结构鉴定如下:
该化合物的1H NMR(500MHz,DMSO-d6)谱中,δ12.78(1H,s)为黄酮5位羟基质子特征信号;δ6.66(1H,d,J=2.0Hz),δ6.40(1H,d,J=2.0Hz)为5,7-二氧间位取代黄酮A环6,8位质子信号;δ6.56(1H,d,J=2.0Hz),δ6.60(1H,dd,J=8.5,2.0Hz),δ7.38(1H,d,J=8.5Hz)为B环ABX耦合系统上3′,5′,6′上质子信号;δ4.88(1H,d,J=7.5Hz),δ5.50(1H,d,J=7.5Hz)为糖的端基质子信号,根据其耦合常数可知葡萄糖端基构型为β构型。δ3.16-3.76之间的多重峰为糖连接羟基的质子信号;δ4.56-5.46之间的双重峰为糖连接的羟基质子信号。
13CNMR(125MHz,DMSO-d6)中,显示27个碳信号,δ149.6,177.5,156.8,162.8,161.1,158.8,160.5为7个连氧季碳,其中δ177.5为羰基碳信号,推测该化合物为黄酮类化合物,δ100.3,77.5,76.8,70.0,73.5,61.0,100.6,72.9,77.0,70.0,73.6,63.5分别为两组葡萄糖碳信号。
HMBC谱中,δ5.50(H-1″)和δ162.8(C-7),δ4.88(H-1″′)和δ160.5(C-4′),存在远程相关,可以确定糖单元与黄酮苷元7位和4’相连。
一级质谱中,负离子模式,碎片离子m/z 625.1349[M-H]-,m/z 1251.2840[2M-H]-;正离子模式,碎片离子m/z 627.1621[M+H]+,m/z 649.1428[M+Na]+,m/z 1275.2779[2M+H]+;从而推测该化合物分子量为626,分子式C27H30O17;二级质谱中,负离子模式,碎片离子m/z 625.1411[M-H]-,m/z 463.0891[M-Glc]-,m/z 301.0344[M-2×Glc]-,m/z151.0033,表明其为黄酮苷类化合物,结合其波谱数据(见表1)鉴定为:7,4′-O-β-D-葡萄糖桑色素苷。
表1 7,4′-O-β-D-葡萄糖桑色素苷核磁数据
其次,本发明提供了该化合物的制备方法:
1)桑枝药材,60%乙醇溶液回流提取3次,每次2小时,提取液减压回收乙醇,醇沉,过夜过滤,浓缩,水沉,过夜后过滤,加入大孔树脂中,依次用乙醇溶液梯度洗脱,收集20%-25%乙醇溶液洗脱,减压浓缩得洗脱液;
2)步骤1中所得洗脱液经反相硅胶柱色谱法分离,以甲醇溶液梯度洗脱,收集20%-30%甲醇洗脱液,减压浓缩得洗脱液;
3)步骤2中所得醇浓缩液经制备液相分离纯化,使用20%-60%甲醇溶液等度洗脱,得到目标化合物。
其中,所述方法步骤1)中的梯度洗脱条件为分别依次用10%、20%、25%、95%乙醇溶液洗脱,其洗脱溶液的用量依次为6、2、2、6倍柱体积。
其中,所述方法步骤2)中梯度洗脱条件为分别用5%、15%、20%、30%、90%甲醇溶液洗脱,其洗脱溶液的用量全部为2倍柱体积。
其中,所述方法步骤3)中等度洗脱浓度为25%甲醇溶液。
再者,本发明提供的化合物具有抗炎活性,可用于制备抗炎药物。二甲苯致小鼠耳片肿胀炎症模型显示,本发明化合物(20,40,80mg/kg)对二甲苯致小鼠耳廓急性炎症有不同程度的抑制作用,其中40和80mg/kg两个剂量组与模型组相比,有显著性差异(22.94%、33.08%);并且,与桑色素相比,本发明化合物对炎症的抑制率更高(22.94%、33.08%vs12.32%、22.67%),具有明显的药效优势。当本发明提供的化合物给药浓度达到80mg/kg,其对二甲苯致小鼠耳片肿胀炎症的抑制率(33.08%)超过阳性药物萘普生40mg/kg(31.82%)。另外,本发明化合物三个剂量组的胃肠道不良反应均明显低于阳性药物组。
本发明取得如下有益效果:
1.提供了一种7,4′-O-β-D-葡萄糖桑色素苷类新化合物,该化合物是桑色素结构中7和4′位羟基被葡萄糖取代的黄酮糖苷类化合物,其在结构中7、4′的羟基被糖基保护,从而在体内不易被清除;另一方面水溶性、脂溶性均较好,其生物利用度更高,故该化合物的抗炎药理活性更好。
2.本发明化合物的原料采用桑枝药材为原料,充分利用了桑树资源,化废为宝,成本低廉。
3.本发明提供的制备方法工艺简单,仅采用乙醇溶液和甲醇溶液作为提取和洗脱溶剂,环境友好;且步骤2)中采用甲醇溶液进行梯度洗脱,收集特定浓度洗脱液,其可以有效去除香豆素糖苷类和二苯乙烯糖苷类成分,提高了化合物的纯度。
4.本发明提供的化合物具有显著的抗炎活性,且其对胃肠道等的不良反应明显低于萘普生西药,可用于制备抗炎药物。
附图说明:
图1为化合物正离子模式一级质谱图
图2为化合物负离子模式一级质谱图
图3为化合物负离子模式二级质谱图
图4为化合物的1HNMR谱图
图5为化合物的13CNMR谱图
图6为化合物的Dept135谱图
图7为化合物的HSQC谱图
图8为化合物的HMBC谱图
具体实施方式
下面将结合具体实施方式进一步说明本发明,但本发明要求保护的范围并不局限于下列实施方式。
实例1化合物7,4′-O-β-D-葡萄糖桑色素苷制备
桑枝药材5kg,60%乙醇溶剂回流提取3次,每次2小时,提取液减压回收乙醇,浓缩至相对密度为1.05,加入95%乙醇至60%乙醇醇沉,过夜后过滤,浓缩至相对密度为1.33,加水水沉,过夜后过滤,浓缩至相对密度1.02,加入大孔树脂HPD100中,依次用乙醇溶液梯度洗脱(10%,20%,25%,30%,40%,95%),分别洗脱6,2,2,2,2,6倍柱体积(BV),收集20%-30%乙醇溶液洗脱液,减压浓缩得浸膏33.11g;经反相硅胶柱色谱法分离,以甲醇溶液梯度洗脱(5%,15%,20%,30%,40%,60%,80%),分别洗脱2BV,得到20%-30%甲醇洗脱液,减压浓缩得粗品1.52g;所得醇浓缩液经制备液相分离,25%甲醇溶液等度洗脱,收集馏分,浓缩干燥得到目标化合物377mg,纯度90.12%。
实施例2化合物7,4′-O-β-D-葡萄糖桑色素苷制备
桑枝药材13kg,60%乙醇溶剂回流提取3次,每次2小时,提取液减压回收乙醇,浓缩至相对密度为1.05,加入95%乙醇至60%乙醇醇沉,过夜后过滤,浓缩至相对密度为1.33,加水水沉,过夜后过滤,浓缩至相对密度1.02,加入大孔树脂HPD100中,依次用乙醇溶液梯度洗脱(10%,20%,25%,95%),分别洗脱6,2,2,6柱体积(BV),收集20%-25%乙醇溶液洗脱液,减压浓缩得浸膏73.56g;经反相硅胶柱色谱法分离,以甲醇溶液梯度洗脱(5%,15%,20%,30%,90%),分别洗脱2BV,得到20%-30%甲醇洗脱液,减压浓缩得粗品4.61g;所得醇浓缩液经制备液相分离,25%甲醇溶液等度洗脱,收集馏分,浓缩干燥得到目标化合物1.21g,纯度98.56%。
实例3化合物7,4′-O-β-D-葡萄糖桑色素苷抗炎活性测试
采用二甲苯诱导的小鼠耳肿胀模型,测试该化合物的抗炎活性。
试验方法:昆明种小鼠50只,雌雄各半,体重20±2g,随机分为5组,每组10只,分别为模型组、受试药物(20,40,80mg/kg)组、阳性药组(萘普生40mg/kg)。
灌胃(ig)给药,每天1次,连续3天,模型组则给予相应体积的0.5%的CMC-Na。末次给药后1h于小鼠左耳前后两面涂抹二甲苯50μL,右耳作对照,1.5h后将小鼠脱颈椎处死,沿耳廓基线剪下两耳,用直径9mm的打孔器分别在同一部位打下圆耳片,用电子天平称重,计算肿胀度(mg)及肿胀抑制率(%)。
肿胀度(mg)=左耳耳片重-右耳耳片重
抑制率=(模型组平均肿胀度-给药组平均肿胀度)/模型组平均肿胀度×100%。
结果与分析:
表1 7,4′-O-β-D-葡萄糖桑色素苷对二甲苯诱导小鼠耳肿胀的影响(x±s,n=10)
*P﹤0.05,**P﹤0.01,νs.Model group
二甲苯能明显诱导小鼠耳肿胀。致炎前连续灌胃给药3天,发现本发明化合物(20,40,80mg/kg)对二甲苯致小鼠耳廓急性炎症有不同程度的抑制作用,其中40和80mg/kg两个剂量组与模型组相比,有显著性差异。并且与桑色素相比,具有明显的药效优势。
实施例4 7,4′-O-β-D-葡萄糖桑色素苷对胃肠道安全性实验
实验方法:50只大鼠按性别、体重随机分为5组,分别为:阴性对照组、受试药物(20、40、80mg/kg)剂量组以及萘普生组,每组10只,雌雄各半。每组大鼠灌胃给予相应药物溶液。给药体积为10ml/kg。给药13d后半数大鼠禁食12h,次日给药lh后颈椎脱臼处死大鼠,立即打开腹腔,在距幽门2cm处结扎,从贲门注入10ml4%甲醛后结扎固定10分钟,沿胃大弯剪开,取出胃及十二指肠,以生理盐水冲洗,展平,置解剖显微镜下测定溃疡面积。
结果与分析:
表2 7,4′-O-β-D-葡萄糖桑色素苷给药14天对大鼠胃肠道的作用(x±s,n=10)
*P﹤0.05,**P﹤0.01,νs.Control group
给予正常大鼠7,4′-O-β-D-葡萄糖桑色素苷连续14天,20和40mg/kg剂量下未引起大鼠胃肠道溃疡。80mg/kg剂量下,有轻微的胃肠道溃疡。与阳性药相比,对胃肠道的不良反应程度明显减轻,溃疡面积以及溃疡动物的发生率明显降低。
结论
二甲苯致小鼠耳片肿胀是最常用的炎症模型,主要表现为局部的充血、水肿及渗出等病理反应。本试验应用这种模型,对受试药抗炎活性进行了筛选。结果显示,本发明化合物7,4′-O-β-D-葡萄糖桑色素苷具有显著的抗炎活性,相比于萘普生,其胃肠道不良反应少且轻。
Claims (3)
2.如权利要求1所述的制备方法,其特征在于,所述方法步骤(1)中的梯度洗脱条件为依次用10%、20%、25%、95%乙醇溶液洗脱,其洗脱溶液的用量依次为6、2、2、6倍柱体积。
3.如权利要求1所述的制备方法,其特征在于,所述方法步骤(2)中梯度洗脱条件为依次用5%、15%、20%、30%、90%甲醇溶液洗脱,其洗脱溶液的用量各为2倍柱体积。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710066556.4A CN108395461B (zh) | 2017-02-07 | 2017-02-07 | 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710066556.4A CN108395461B (zh) | 2017-02-07 | 2017-02-07 | 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108395461A CN108395461A (zh) | 2018-08-14 |
CN108395461B true CN108395461B (zh) | 2022-01-07 |
Family
ID=63094065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710066556.4A Active CN108395461B (zh) | 2017-02-07 | 2017-02-07 | 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108395461B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069926A1 (de) * | 2001-03-02 | 2002-09-12 | Merck Patent Gmbh | Kosmetische formulierung enthaltend flavonoid-derivate |
CN1382478A (zh) * | 2002-05-14 | 2002-12-04 | 南京大学 | 桑枝提取物及其提取方法和新用途 |
CN1668287A (zh) * | 2001-09-06 | 2005-09-14 | 赛诺克思公司 | 通过3-脱氧类黄酮来抑制t淋巴细胞活性及其相关疗法 |
CN1699393A (zh) * | 2005-06-09 | 2005-11-23 | 复旦大学 | 黄酮苷类化合物及其制备方法 |
WO2007084857A2 (en) * | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Methods and compositions for treating cell proliferative disorders |
CN101496834A (zh) * | 2009-02-12 | 2009-08-05 | 浙江康恩贝制药股份有限公司 | 桑枝黄酮和二苯乙烯类提取物的制备方法 |
CN102688261A (zh) * | 2011-03-21 | 2012-09-26 | 苏州世林医药技术发展有限公司 | 一种凤尾草提取物及其制备方法和用途 |
CN103159807A (zh) * | 2013-03-27 | 2013-06-19 | 苏州大学 | 一种桑枝提取物及其制备方法 |
CN104083390A (zh) * | 2014-06-28 | 2014-10-08 | 广西大学 | 6,7-二羟基-5-β-D-吡喃葡萄糖-4`-β-O-D-吡喃葡萄糖黄酮在制备抗炎药物中的用途 |
CN105343118A (zh) * | 2015-12-17 | 2016-02-24 | 广西大学 | 5,7-二羟基-4`-O-(6``-O-β-D-葡萄糖)-β-D-葡萄糖黄酮在制备抗炎药物中的应用 |
-
2017
- 2017-02-07 CN CN201710066556.4A patent/CN108395461B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069926A1 (de) * | 2001-03-02 | 2002-09-12 | Merck Patent Gmbh | Kosmetische formulierung enthaltend flavonoid-derivate |
CN1668287A (zh) * | 2001-09-06 | 2005-09-14 | 赛诺克思公司 | 通过3-脱氧类黄酮来抑制t淋巴细胞活性及其相关疗法 |
CN1382478A (zh) * | 2002-05-14 | 2002-12-04 | 南京大学 | 桑枝提取物及其提取方法和新用途 |
CN1699393A (zh) * | 2005-06-09 | 2005-11-23 | 复旦大学 | 黄酮苷类化合物及其制备方法 |
WO2007084857A2 (en) * | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Methods and compositions for treating cell proliferative disorders |
CN101496834A (zh) * | 2009-02-12 | 2009-08-05 | 浙江康恩贝制药股份有限公司 | 桑枝黄酮和二苯乙烯类提取物的制备方法 |
CN102688261A (zh) * | 2011-03-21 | 2012-09-26 | 苏州世林医药技术发展有限公司 | 一种凤尾草提取物及其制备方法和用途 |
CN103159807A (zh) * | 2013-03-27 | 2013-06-19 | 苏州大学 | 一种桑枝提取物及其制备方法 |
CN104083390A (zh) * | 2014-06-28 | 2014-10-08 | 广西大学 | 6,7-二羟基-5-β-D-吡喃葡萄糖-4`-β-O-D-吡喃葡萄糖黄酮在制备抗炎药物中的用途 |
CN105343118A (zh) * | 2015-12-17 | 2016-02-24 | 广西大学 | 5,7-二羟基-4`-O-(6``-O-β-D-葡萄糖)-β-D-葡萄糖黄酮在制备抗炎药物中的应用 |
Non-Patent Citations (4)
Title |
---|
3-O-Methylquercetin Glucosides from Ophioglossum pedunculosum and Inhibition of Lipopolysaccharide-Induced Nitric Oxide Production in RAW 264.7 Macrophages;Chuan-Xing Wan et al.;《Helvetica Chimica Acta》;20121231;第95卷;第1586-1592页 * |
Anti-inflammatory effects of phenolic extracts from strawberry and mulberry fruits on cytokine secretion profiles using mouse primary splenocytes and peritoneal macrophages;Chieh-Jung Liu et al.;《International Immunopharmacology》;20130413;第16卷;第165-170页 * |
HPLC-PDA-MS and NMR Characterization of a Hydroalcoholic Extract of Citrus aurantium L. var. amara Peel with Antiedematogenic Activity;Teresa Mencherini et al.;《J. Agric. Food Chem.》;20120910;第61卷;第1686-1693页 * |
桑枝总黄酮体外抗炎活性及机制研究;章丹丹 等;《时珍国医国药》;20101231;第21卷(第11期);第2787-2790页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108395461A (zh) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006510592A (ja) | スイカズラ(LonicerajaponicaThunb.)茎の活性成分の抽出および精製方法、その消炎鎮痛剤への用途 | |
CN101781355B (zh) | 柠檬苦素的制备方法及组合物和其应用 | |
CN102342945A (zh) | 救必应皂苷化合物用于制备抗炎镇痛药物 | |
US20040067263A1 (en) | Method for preparating an anemone raddeana extract and the pharmaceutical composition containing the same as well as use thereof | |
CN102304158B (zh) | 酰化黄酮苷化合物及其在制备补体抑制剂药物中的应用 | |
WO2024031997A1 (zh) | 一种n-n-双-恶唑烷酮生物碱类化合物、制备方法及在医药领域的应用 | |
CN111253247B (zh) | 一种具有抗炎活性的新酚酸类化合物的制备方法及应用 | |
CN108395461B (zh) | 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 | |
CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
CN101914002A (zh) | 一种蓝萼甲素的提取方法 | |
CN105503988B (zh) | 天然抗癫痫活性化合物及其在药物制剂中的用途 | |
CN103232518B (zh) | 一种新海蓬子降三萜类皂苷化合物及其制备方法和用途 | |
CN110467522B (zh) | 一种青黛中具有抗肠炎活性的二苯乙烯类化合物及其制备方法、应用 | |
CN109810153B (zh) | 芳香取代葡萄糖类化合物及其药物组合物的制备方法与镇痛应用 | |
CN106977561B (zh) | Sutherlandin-5-p-hydroxybenzoate的制备及其在制备治疗类风湿关节炎药物中的应用 | |
CN102485741A (zh) | 降甲基齐墩果烷型三萜类化合物及其制备方法和应用 | |
CN106146600A (zh) | 乳香五环三萜酸类化合物或其盐、其组合物在制备糖尿病治疗药物中的用途 | |
CN106977560B (zh) | 2S-cardiospermin-5-benzoate的制备及其在制备治疗类风湿关节炎药物中的应用 | |
CN104116753A (zh) | 桃叶珊瑚苷在制备治疗特发性肺纤维化药物中的应用 | |
CN109908120B (zh) | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 | |
CN109091602A (zh) | 韭菜子有效成分、提取方法及其在制备保护肝损伤药物方面的应用 | |
CN113061153B (zh) | 吲哚苷类化合物、其制备方法及其应用 | |
CN114409544B (zh) | 具有血管舒张活性的苯丙素及其提取方法和应用 | |
EP2848251B1 (en) | Extracts and isolated compounds from Cakile arabica for treatment of ulcer | |
CN107641143A (zh) | 从昆明山海棠中提取雷公藤甲素和雷公藤红素的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |